DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

B. Riley FBR Maintains Buy on Spectrum Pharmaceuticals, Lowers Price Target to $8

B. Riley FBR analyst Mayank Mamtani maintains Spectrum Pharmaceuticals (NASDAQ:SPPI) with a Buy and lowers the price target from $11 to $8.

Benzinga · 03/02/2020 12:57

B. Riley FBR analyst Mayank Mamtani maintains Spectrum Pharmaceuticals (NASDAQ:SPPI) with a Buy and lowers the price target from $11 to $8.